SCHEMBL4607822

SCHEMBL4607822

Cc1cc(I)cc2c(Cl)c(C(N)=O)nnc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.37
SYK P43405 1/20 0.36
BTK Q06187 3/20 0.34
LCK P06239 2/20 0.34
POLB P06746 1/20 0.34
TEC P42680 2/20 0.33
BMX P51813 2/20 0.33
LYN P07948 1/20 0.33
HCK P08631 1/20 0.33
FGR P09769 1/20 0.33
SRC P12931 1/20 0.33
FRK P42685 1/20 0.33
BLK P51451 1/20 0.33
LIMK1 P53667 1/20 0.33
ACVR1 Q04771 1/20 0.33
TNK2 Q07912 1/20 0.33
ITK Q08881 1/20 0.33
LMNA P02545 1/20 0.32
LRRK2 Q5S007 2/20 0.31
PARP4 Q9UKK3 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4606147 0.82 LMNA (0.32) SYKLMNA
SCHEMBL14007381 0.82
SCHEMBL4607457 0.80 SLC2A1 (0.49) SLC2A1SYKBTKLCKPOLB
SCHEMBL4607581 0.79 LRRK2 (0.41) SLC2A1SYKLRRK2
SCHEMBL4607685 0.77 SLC2A1 (0.44) SLC2A1SYKBTKLCKPOLB
SCHEMBL4922413 0.77 SLC2A1 (0.65) SLC2A1SYKBTKLCKPOLB
SCHEMBL5805608 0.77 POLB (0.47) SLC2A1POLBLMNAPARP4PIM1
SCHEMBL5321604 0.75 SLC2A1 (0.63) SLC2A1BTKPOLBPIM1PIM2
SCHEMBL4607280 0.73 LCK (0.44) BTKLCKLMNALRRK2
SCHEMBL14059201 0.70 LCK (0.41) BTKLCKLRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080280911-A1 Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) GLAXO GROUP LIMITED (GB) 2008-11-13 US disclosed
US-20080280911-A1 Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) GLAXO GROUP LIMITED (GB) 2008-11-13 US disclosed
EP-1945616-A1 CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) GLAXO GROUP LIMITED (GB) 2008-07-23 EP disclosed
WO-2007045861-A1 CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) GLAXO GROUP LIMITED (GB) 2007-04-26 WO disclosed
WO-2007045861-A1 CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) GLAXO GROUP LIMITED (GB) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280911-A1 Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) PDE4A, PDE4B, PDE3B SLC2A1 3751/4885SYK 4333/4885BTK 2607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.